Who Paid My Doc
Minisha Sood
Endocrinology, Diabetes & Metabolism New York, NY Medical Doctor
NPI 1144420043 CMS profile 1249632
1080 5Th Ave, Suite 1A, New York, NY 10128
General payments
$90,681
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Minisha Sood of New York, NY is reported in the CMS Open Payments database as having received $90,681 across 802 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 93rd percentile of Endocrinology, Diabetes & Metabolism profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $2,332 | 101 | |
| 2024 | General | $2,225 | 109 | |
| 2023 | General | $6,484 | 128 | |
| 2022 | General | $3,867 | 121 | |
| 2021 | General | $18,581 | 123 | |
| 2020 | General | $21,541 | 83 | |
| 2019 | General | $35,652 | 137 |
Beside peers
- Minisha Sood
- Endocrinology, Diabetes & Metabolism median
- Middle half of Endocrinology, Diabetes & Metabolism
- National median
In program year 2025, general payments to Minisha Sood were reported at $2,332. Among 5,868 Endocrinology, Diabetes & Metabolism profiles paid that year, the median was $507 and the middle half received between $135 and $1,838.
Show as a table
| Year | Minisha Sood | Endocrinology, Diabetes & Metabolism median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $35,652 | $494 | $123–$2,253 | $163 |
| 2020 | $21,541 | $335 | $85–$1,841 | $114 |
| 2021 | $18,581 | $398 | $88–$1,981 | $132 |
| 2022 | $3,867 | $364 | $88–$1,568 | $149 |
| 2023 | $6,484 | $420 | $113–$1,614 | $160 |
| 2024 | $2,225 | $440 | $121–$1,646 | $164 |
| 2025 | $2,332 | $507 | $135–$1,838 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 21 drugsPart D claims
795
Drug cost
$399,340
Branded share of claims
61%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Mounjaro Tirzepatide | Brand | 110 | $131,009 | |
| Tymlos Abaloparatide | Brand | 18 | $85,007 | |
| Ozempic Semaglutide | Brand | 60 | $65,980 | |
| Jardiance Empagliflozin | Brand | 39 | $39,008 | |
| Wegovy Semaglutide | Brand | 11 | $13,730 | |
| Trulicity Dulaglutide | Brand | 12 | $13,697 | |
| Tresiba Flextouch U-200 Insulin Degludec | Brand | 12 | $12,410 | |
| Toujeo Solostar Insulin Glargine,hum.Rec.Anlog | Brand | 25 | $9,232 | |
| Synthroid Levothyroxine Sodium | Brand | 64 | $6,989 | |
| Tirosint Levothyroxine Sodium | Brand | 35 | $6,731 |
The 10 drugs with the highest cost, of 21 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 6,527 Part D prescribers listed as Endocrinology; they describe a distribution and say nothing about conduct.
Payments and prescribing
First 5 of 32 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| Veozah |
|
$230 | — | — |
| AFREZZA |
|
$182 | — | — |
| Wegovy |
|
$164 | 11 | — |
| JARDIANCE |
|
$159 | 39 | — |
| Ozempic |
|
$146 | 60 | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
See more in the dashboard: 25 with a free account, all 32 with PatronRecords
802 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Endocrinology, Diabetes & Metabolism in New York
Robert Busch
Endocrinology, Diabetes & Metabolism · Albany, NY
Michael Shanik
Endocrinology, Diabetes & Metabolism · Smithtown, NY
Ajay Chaudhuri
Endocrinology, Diabetes & Metabolism · Buffalo, NY
Vinay Kapoor
Endocrinology, Diabetes & Metabolism · Manhasset, NY
John Bilezikian
Endocrinology, Diabetes & Metabolism · New York, NY
Barbara Hirsch
Endocrinology, Diabetes & Metabolism · Manhasset, NY
Related records
Endocrinology, Diabetes & Metabolism in New York
Practitioners in the same specialty and state, ranked by reported value.
All Endocrinology, Diabetes & Metabolism
Everyone recorded under this specialty, nationwide.
Doctors in New York
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.